Le Chevalier T, Gottfried M
Institut Gustave-Roussy, Villejuif, France.
Semin Oncol. 1997 Apr;24(2 Suppl 7):S7-47-S7-49.
Gemcitabine is a novel nucleoside analogue that has demonstrated activity against several solid tumors. A large phase II study has been performed in Europe and Canada with a total enrollment of 161 non-small cell lung cancer patients, 26 of whom were from the Institut Gustave-Roussy. Patient characteristics were the same for our patients and the whole study population. One hundred fifty-one patients, including 24 at our institution, were evaluable for response. We observed an objective response rate of 21.8% (95% confidence interval, 15.5% to 29.3%) and median survival of 9.4 months for the whole population (7.5 months at our institution), with a 1-year survival rate of 42% (38% at our institution). Tolerance was good in the majority of patients. These results suggest that gemcitabine can be considered a safe and active agent for the treatment of patients with advanced non-small cell lung cancer.
吉西他滨是一种新型核苷类似物，已证明对多种实体瘤具有活性。在欧洲和加拿大进行了一项大型II期研究，共纳入161例非小细胞肺癌患者，其中26例来自古斯塔夫 - 鲁西研究所。我们的患者与整个研究人群的患者特征相同。151例患者（包括我们机构的24例）可评估疗效。我们观察到总体客观缓解率为21.8%（95%置信区间，15.5%至29.3%），总体中位生存期为9.4个月（我们机构为7.5个月），1年生存率为42%（我们机构为38%）。大多数患者耐受性良好。这些结果表明，吉西他滨可被视为治疗晚期非小细胞肺癌患者的一种安全有效的药物。
